Rigel Pharmaceuticals Deal History & Licensing Activity
Rigel Pharmaceuticals is a large biotech headquartered in US. Over the past three years, Rigel Pharmaceuticals has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 15 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
2
Active Trials
15
Top Modality
Small Molecules
Focus Area
Hematological Malignancies
Rigel Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Rigel Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Veppanu | Arvinas | Small Molecules | Approved | license | May 15, 2026 |
| VEPPANU (vepdegestrant) | Arvinas and Pfizer | Small Molecules | Approved | license | May 12, 2026 |
Rigel Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Rigel Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Rigel Pharmaceuticals Strategic Signals
Key indicators of Rigel Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Rigel Pharmaceuticals Clinical Pipeline
Rigel Pharmaceuticals has 15 active clinical trials across 4 development phases.
1
Phase 4
5
Phase 1
8
Phase 2
1
Phase 3
See How Your Asset Matches Rigel Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Rigel Pharmaceuticals Licensing & Deal Activity
Rigel Pharmaceuticals is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Rigel Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Rigel Pharmaceuticals include Hematological Malignancies (6 deals and trials), Oncology (4 deals and trials), Autoimmune (3 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Rigel Pharmaceuticals has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Rigel Pharmaceuticals and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Rigel Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.